clinical trial · NCT04842604
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
Pfizer·phase3·completed·n = 14
Acute Myeloid LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic LeukemiaGlasdegibAzacitidine
brief summary
An open-label study available to all eligible participants from Study B1371019 and participants originating from Study B1371012 continuing on study intervention with azacitidine with or without glasdegib.
started
May 17, 2021
primary completion
Dec 2, 2022
completion
Dec 2, 2022
last updated
Dec 18, 2023
official title
A MULTI-CENTER CONTINUATION STUDY EVALUATING AZACITIDINE WITH OR WITHOUT GLASDEGIB (PF-04449913) IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA, MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol